Cordlife Preimplantation Genetic Screening (PGS)

Cordlife PGS (Preimplantation Genetic Screening) is the procedure of evaluating embryos for chromosomal aneuploidy, the presence of either addition or loss of chromosomes in embryos generated from chromosomally normal parents. In conjunction with in vitro fertilization (IVF) treatment, Cordlife PGS helps to improve the likelihood of a successful pregnancy while reducing the chance of miscarriage or having a child with gross chromosomal disorders.

“Research has shown that transfer an embryo after PGS has higher rate of a successful pregnancy, from 22% to 41%.1

Who should consider Cordlife PGS?

PGS test is highly beneficial to women above 37 years old. This test helps to improve pregnancy and live birth rate.

Women of advanced
maternal age

Women with recurrent
pregnancy loss

Men with infertility
issues

Women with repeated implantation failure

Carriers of chromosomal
abnormalities

Mothers who had given birth to a child with chromosomal abnormalities

Why Cordlife PGS?

Comprehensive Test

Screens all 23 pairs of chromosomes

Employs Next Generation Sequencing (NGS)

screen for embryo aneuploidy and/or DNA gains or losses (larger than 20Mb)

Highest Quality Assurance

Tested by largest prenatal laboratory in Taiwan with CAP-accreditation and illumina CSPro-certified process

Quick Turnaround

Test result will be available within 3 weeks from the date of sample receipt by the laboratory

99.9%3

Accuracy rate

5 Simple Steps To Enrol Cordlife PGS

Step 1: Consultation

Consult your doctor or fertility specialist

Step 2: Collection

Doctor or fertility specialist will collect samples (Trophectoderm cells / Blastocyst).

Step 3: Sequence

Your samples will be delivered to the sequencing laboratory in Taiwan for analysis.

Step 4: Report

Reports will be available in 3 weeks.

Step 5: Transfer

Based on the PGS test results, your doctor or fertility specialist will select and transfer healthy embryos to the uterus.

Enrolling Cordlife PGS

Cordlife PGS must be prescribed by your obstetrician who will explain the details about PGS to ensure the test is suitable for you. Please enquire with your obstetrician today or send us an email.

Caution

No test is perfect. The results of the PGS test are specific to the samples it tests. The results of these tests are useful as supporting evidence for healthcare providers, and do not represent a final diagnostic conclusion. PGS test results are NOT a diagnostic test. If a chromosomal abnormality (aneuploidy/deletion/duplication) is found, it is the responsibility of the health care provider to provide guidance and recommendations according to current knowledge regarding the disorder. Although the results of these tests are generally conclusive, not all chromosomal abnormalities may be detected, depending on chromosomal or embryonic status or other causes.

Cordlife PGS brought to you by CL BIOTECH COMPANY LIMITED cooperates with a laboratory based in Taiwan - Genetics Generation Advancement Corp. (GGA).

Source:

  1. Liss J, Pastuszek E, Pukszta S et al. Effect of next-generation sequencing in preimplantation genetic testing on live birth ratio. Reprod Fertil Dev. 2018;30(12):1720-1727.
  2. Kang, Hey-Joo et al. Preimplantation genetic screening: who benefits?
    Fertility and Sterility. 2016; 106(3):597 – 602. https://www.fertstert.org/article/S0015-0282(16)61124-X/fulltext . Accessed March 5, 2019.
  3. Fiorentino F, Biricik A, Bono S et al. Development and validation of a next-generation sequencing-based protocol for 24-chromosome aneuploidy screening of embryos. Fertile Sterile. 2014;101(5):1375-82. https://www.ncbi.nlm.nih.gov/pubmed/24613537 . Accessed December 5, 2019.